Smith & Nephew SNATS, Inc. (NYSE:SNN) Given Average Rating of “Hold” by Brokerages

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have been given an average rating of “Hold” by the ten ratings firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $30.9250.

Several equities analysts have commented on the stock. Barclays cut shares of Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, August 5th. Canaccord Genuity Group cut their price objective on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a research report on Monday, May 11th. Wall Street Zen upgraded Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a research note on Monday. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Smith & Nephew SNATS in a report on Thursday, August 6th. Finally, Zacks Research cut Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a research note on Friday, August 7th.

Institutional Trading of Smith & Nephew SNATS

A number of large investors have recently made changes to their positions in SNN. Clearstead Trust LLC acquired a new stake in Smith & Nephew SNATS in the second quarter valued at approximately $25,000. Addison Advisors LLC purchased a new position in Smith & Nephew SNATS in the second quarter worth approximately $43,000. Allworth Financial LP acquired a new position in Smith & Nephew SNATS during the 2nd quarter worth approximately $48,000. Garner Asset Management Corp acquired a new position in Smith & Nephew SNATS during the 4th quarter worth approximately $27,000. Finally, Arax Advisory Partners increased its position in shares of Smith & Nephew SNATS by 142.6% in the 4th quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 569 shares during the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Trading Down 0.6%

Shares of SNN stock opened at $29.14 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14. The company has a 50 day moving average price of $30.24 and a 200 day moving average price of $31.70. Smith & Nephew SNATS has a fifty-two week low of $28.56 and a fifty-two week high of $38.79.

Smith & Nephew SNATS Announces Dividend

The business also recently disclosed a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be paid a $0.312 dividend. This represents a dividend yield of 205.0%. The ex-dividend date is Friday, October 2nd.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.